Global R&D Center_R&D

Global R&D Center

2021-10-28
Nature Dialogue with Dr. Aimin Hui: How to Lead R&D of Innovator Drugs?

Chinese pharmaceutical companies are turning their attention to innovation, shifting rapidly from mastery of follow-on drugs to researching first-in-class and best-in-class drugs. Aiming to be a healthcare group with a global presence, Fosun Pharma, established in Shanghai in 1994, has built its core business around innovative drug R&D and manufacturing.

More
2021-10-07
Innovation for Health — The Fourth Hongqiao International Health Technology Innovation Forum Held in Shanghai

On November 6, 2021, as a parallel supporting event of the 4th China International Import Expo (CIIE), the 4th Hongqiao International Health Technology Innovation Forum with the theme of "Innovation for Good Health" was successfully held. This forum was sponsored by the International Health Exchange and Cooperation Center NHC PRC (IHECC) and China Pharmaceutical Innovation and Research Development Association,

More
2021-09-28
2021 CSCO | Henlius Publishes Newest Phase II Clinical Data of Novel Anti-PD-1 mAb Serplulimab for Treatment of Advanced Cervical Cancer

In this meeting, Henlius releases phase 2 study results of serplulimab (HLX10, novel anti-PD-1 antibody), in patients with advanced cervical cancer in an oral presentation.

More
2021-09-28
2021 CSCO | Henlius Publishes Phase III Clinical Data of Bevacizumab Biosesimilar HLX04 for Treatment of Metastatic Colorectal Cancer

In this meeting, Henlius releases phase 3 study results of HLX04 (bevacizumab biosesimilar), in patients with metastatic colorectal cancer in an oral presentation.

More

Fosun Pharma started its innovation and R&D in 2009 and made great progress in R&D efficiency, system construction and international influence since 2017.

By the end of 2022, Fosun Pharma had more than 260 projects for drugs under development, including innovator drugs, biosesimilars, generic drugs, and those for consistency evalsuation. During the reporting period, the company applied for 249 patents in the pharmaceutical segment, including 16 US patents and 17 PCT applications, and was granted 48 patents.

According to 2022 Annual Report
*Unit: RMB billion yuan

5.097 billion

The R&D investment in the pharmaceutical business
5.885 billion

The R&D investment
3,600+

R&D staff
1,900+

employees with a master's degree or above

In China

20

Concurrent clinical trials
7

IND applications
3

NDA applications

In The United States And Australia

3

Clinical trials
1

IND application
2 项

IND approvals

High-tech: PCG - protein therapy, cell therapy, gene therapy, small molecule pioneering/best innovator drugs

Double-antibody
Stem cell therapy
mRNA therapy
Gene editing

Tumor/immunology, neurological disorders (chronic degeneration, stroke, etc.), chronic/metabolic diseases, infectious/rare diseases

Tumor/immunology
Central Nervous System
Metabolic/chronic diseases
Infectious/rare diseases

Z6·尊龙凯时「中国」官方网站

Z6·尊龙凯时「中国」官方网站Z6·尊龙凯时「中国」官方网站

Our Company

Our Business

R&D

Sustainability

Investor Relations

News

Careers

Global R&D Center

Nature Dialogue with Dr. Aimin Hui: How to Lead R&D of Innovator Drugs?

Innovation for Health — The Fourth Hongqiao International Health Technology Innovation Forum Held in Shanghai

2021 CSCO | Henlius Publishes Newest Phase II Clinical Data of Novel Anti-PD-1 mAb Serplulimab for Treatment of Advanced Cervical Cancer

2021 CSCO | Henlius Publishes Phase III Clinical Data of Bevacizumab Biosesimilar HLX04 for Treatment of Metastatic Colorectal Cancer

Fosun Pharma started its innovation and R&D in 2009 and made great progress in R&D efficiency, system construction and international influence since 2017.

According to 2022 Annual Report
*Unit: RMB billion yuan

The R&D investment in the pharmaceutical business

The R&D investment

R&D staff

employees with a master's degree or above

In China

In The United States And Australia

Z6·尊龙凯时「中国」官方网站Z6·尊龙凯时「中国」官方网站

Our Company

Our Business

R&D

Sustainability

Investor Relations

News

Careers

Global R&D Center

Nature Dialogue with Dr. Aimin Hui: How to Lead R&D of Innovator Drugs?

Innovation for Health — The Fourth Hongqiao International Health Technology Innovation Forum Held in Shanghai

2021 CSCO | Henlius Publishes Newest Phase II Clinical Data of Novel Anti-PD-1 mAb Serplulimab for Treatment of Advanced Cervical Cancer

2021 CSCO | Henlius Publishes Phase III Clinical Data of Bevacizumab Biosesimilar HLX04 for Treatment of Metastatic Colorectal Cancer

Fosun Pharma started its innovation and R&D in 2009 and made great progress in R&D efficiency, system construction and international influence since 2017.

According to 2022 Annual Report *Unit: RMB billion yuan

The R&D investment in the pharmaceutical business

The R&D investment

R&D staff

employees with a master's degree or above

In China

In The United States And Australia

According to 2022 Annual Report
*Unit: RMB billion yuan